Lecture 2 Overview of the Drug Discovery Process. Target identification and selection.

1. Lecture 2 • Overview of the Drug Discovery Process. Target identification and selection.

2. 1. The Drug Discovery Process: • Drug discovery is an expensive and time-consuming. • Retrospective analyses of the pharmaceutical industry during the 1990s estimate that each new drug in the market takes an average 14 years to develop, costing in the region of $800 million. • In addition one in nine compounds that enters clinical trials makes it to the market.

3. For a drug to work, it has to interact with a disease target (e.g. receptor, enzyme or nucleic acid)in our body and intervene in its way ward functions. • An analogy is the lock and key comparison, with the lock being the disease target and the key representing the drug. The correct key has to be found to turn the lock and open the door to treat the disease.

4. Disease Mechanism • The disease mechanism defines the possible cause or causes of a particular disorder, as well as the path or phenotype of the disease. Understanding the disease mechanism directs research and formulates a possible treatment to slow or reverse the disease process. It also predicts a change of the disease pattern and its implications. • Disease mechanisms can be broadly classified into the following groups • * Defects in distinct genes—genetic disorders • * Infection by bacteria, fungi, or viruses • * Immune/autoimmune disease • * Trauma and acute disease based on injury or organ failure • * Multicausaldisease

5. Target Type and Drugability • Target Type and Drugability, Targets for therapeutic intervention can be broadly classified into these categories: • * Receptors • * Proteins and enzymes • * DNA • * RNA and ribosomal targets • The "drugability" of a given target is defined either by how well a therapeutic, such as small molecule drugs or antibodies, can access the target, or by the efficacy a therapeutic can actually achieve. A long list a parameters influences drugability of a given target; these include cellular location, development of resistance, transport mechanisms such as export pumps, side effects, toxicity, and others.

6. Target Identification. • The starting point for a target-oriented drug-discovery project is to identify a relevant target. • The first requirement in conventional drug discovery is identification of a valid target, a molecule which has a link with the disease of interest such that pharmacological intervention would be expected to cure the disease or ameliorate its symptoms.

7. There are a number of techniques used for target identification. • Radio ligand binding was a common technique until recently. • Now DNA microarrays, expressed sequence tags are used.

8. Radio ligand Binding: • The classic method to discover drug targets or receptors is to bind the potential receptors with radio ligands, so that targets can be picked out from a pool of other receptors. • Bound receptors are then separated from the radio ligands and sequenced. • Potential drug molecules are then studied with these receptors or their nucleotide sequences to determine their interactionsin terms of biochemical and functional properties.

9. DNA Microarray: • DNA microarray, also known as DNA or gene chips, is a technology to investigate how genes interact with one another and how they control biological mechanisms in the body. • The gene expression profile is dynamic and responds to external stimuli rapidly. By measuring the expression profile, scientists can assess the clues for the regulatory mechanisms, biochemical pathways, and cellular functions. • In this way, microarrays enable scientists to find out the target genes that cause disease.

10. Microarrays: • To use the microarray, a known sequence of short DNA is printed on a solid support of membrane or glass slide. • From healthy and diseased cells, mRNAs are isolated. • The mRNAs are used to generate complementary DNAs (cDNAs). • Fluorescent tags are attached to the cDNAs, and the cDNAsare then mixed and incubated with the microarray supports (slides).

11. Microarray slides (Photo courtesy of Thermo Fisher Scientific).

12. Selecting a drug target1- Drug targets • Once a therapeutic area has been identified, the next stage is to identify a suitable drug target (e.g. receptor, enzyme or nucleic acid) • Understanding which bio macromolecules are involved in a particular disease state is very important. This will allow the medicinal chemist whether agonist or antagonist to be designed for a particular receptor or whether inhibitors should be designed for a particular enzyme.

13. Receptor Biochemical reactions activated Agonist Membrane Agonist binding to receptor initiates biochemical reactions Biochemical reactions blocked Antagonist Membrane Antagonist binding to receptor blocks biochemical reactions.

14. Selecting a drug target2- Discovering drug targets If a drug or a poison produces a biological effects, there must be a molecular target for that agent in the body. In the past, the discovery of drug targets depends on finding the drug first. Then, natural chemical messengers started to be discovered. But many targets still stay hidden (orphan receptors i.e, novel receptors whose endogenous ligand is unknown ) and their chemical messengers are also unknown.

15. The challenge is to find a chemical that will interact with these targets in order to find their function and whether they will be suitable as drug targets. This is one of the main driving forces behind the rapidly expanding area of Combinatorial synthesis (synthesis of a large number of compounds in a short period of time using different reagents and starting material and are tested for activity.)

16. Selecting a drug target3-Target specificity and selectivity between species • Target specificity and selectivity is a crucial factor in modern medicinal chemistry research. • The more the selective a drug is for its target, the less chance that it will interact with different targets and have less undesirable side effects. • For example, penicillin target an enzyme involved in bacterial cell wall biosynthesis. Mammalian cells does not have a cell wall, so this enzyme is absent in human cells and penicillin has few side effects.

17. Selecting a drug target4-Target specificity and selectivity within the body Selectivity is also important for drug acting on targets within the body. Enzyme inhibitors should only inhibit the target enzyme and not some other enzyme.

18. Target Validation: After a drug target has been identified, a rigorous evaluation must occur to demonstrate that modulation of the target will have the desired therapeutic effect.  This involves intensive in vitro, as well as in vivo studies that provide information on the effects of biotherapeutic intervention.

19. Isothermal Titration Calorimetry (ITC)can play a critical role in the determination of the mechanism of action of a specified target pathway.  It is impossible to screen for unknown biotherapeutic targets. ITC measures the natural heat generated or absorbed in any biomolecular interaction.  There is no requirement for any prior knowledge of the binding partners, substrates or other cofactors.

20. * Isothermal titration calorimetry (ITC) is a physical technique used to determine the thermodynamic parameters of interactions in solution.* It is most often used to study the binding of small molecules (such as medicinal compounds) to larger macromolecules (proteins, DNA etc.).

21. chemicaldiversity proteintargets identify‘hit’ optimize‘hit’ structure database /genes test safety/efficacy animals humans The Drug Discovery Process The aim is to translate new information into new therapies

22. Different Method of Discovering New Chemical Entities (NCE).